Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Compass To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Compass stock or options between May 1, 2024 and May 7, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , May 16, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Compass …

There's a well-known saying in the investing world, which advises investors to “sell in May and go away.

CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss a new leadership shakeup at drug-maker Novo Nordisk.

The average of price targets set by Wall Street analysts indicates a potential upside of 81% in Vertical Aerospace (EVTL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 44.7% in Aris Mining Corporation (ARMN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The mean of analysts' price targets for Candel Therapeutics (CADL) points to a 311% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The mean of analysts' price targets for Immunocore (IMCR) points to an 114.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The mean of analysts' price targets for Seres Therapeutics (MCRB) points to a 713.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 26.2% in Zoetis (ZTS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 103.6% in Backblaze (BLZE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The consensus price target hints at a 132.4% upside potential for Stoke Therapeutics (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

The average of price targets set by Wall Street analysts indicates a potential upside of 35% in SkyWater Technology (SKYT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Palo Alto Networks' strong product base, robust go-to-market strategy and accelerated product adoption make it a stock worth holding before Q3 earnings.

ATLANTA, May 16, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about Iovance's business, operations, and prospects, including allegations that: (1) new Authorized Treatment Centers (“ATCs”) were experiencing longer timelines to begin treating patients with Amtagvi; (2) Iovance's sales team and new ATCs were ineffective in patient identification and patient selection for Amtagvi, leading to higher patient drop-offs; and (3) the foregoing dynamics led to higher costs and …

The current Alphabet stock discount is drawing a good deal of interest from the 15 analysts who have a current average price target of $202.77.

Take-Two Interactive CEO Strauss Zelnick said Friday the recent delay of the highly-anticipated Grand Theft Auto VI release shows the company's desire to "polish and create the best possible experience for consumers."

Google is facing multiple threats to its search traffic dominance from AI, and one niche where the internet giant is responding with agentic AI is within travel. OpenAI offers its Operator tool for booking vacations, and both it and Microsoft Copilot have deals with Expedia for travel planning.

NEW YORK, NY / ACCESS Newswire / May 16, 2025 / If you suffered a loss on your Open Lending Corporation (NASDAQ:LPRO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/open-lending-corporation-lawsuit-submission-form?prid=148910&wire=1&utm_campaign=18 or contact Joseph E. Levi, Esq.

Atlassian is misunderstood; heavy R&D spending is a strategic investment in future growth, not a red flag. Subscription revenue is booming, up 18.8% year-over-year, and international expansion is accelerating, creating long-term upside. Short-term losses are a conscious trade-off for long-term dominance; strong cash flow and gross margins support this strategy.

NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ:IOVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Iovance securities between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period").